{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:16:39Z","timestamp":1767842199647,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["4840-302-260"],"award-info":[{"award-number":["4840-302-260"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.057","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:10:10Z","timestamp":1559034610000},"page":"3820-3824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study"],"prefix":"10.1016","volume":"37","author":[{"given":"Chang Kyung","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nak-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-eun","family":"Rhie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Kyoung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyoeng Gyun","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2344-7695","authenticated-orcid":false,"given":"Myoung-don","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.057_b0005","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.05.057_b0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1128\/JB.186.1.164-178.2004","article-title":"Formation and composition of the Bacillus anthracis endospore","volume":"186","author":"Liu","year":"2004","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2019.05.057_b0015","unstructured":"An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Washington (DC); 2002."},{"key":"10.1016\/j.vaccine.2019.05.057_b0020","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1586\/14760584.2016.1162104","article-title":"Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less","volume":"15","author":"Schiffer","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.05.057_b0025","doi-asserted-by":"crossref","unstructured":"Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL. The Anthrax Vaccine: Is It Safe? Does It Work? Washington (DC); 2002.","DOI":"10.21236\/ADA403352"},{"key":"10.1016\/j.vaccine.2019.05.057_b0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","article-title":"Development of an improved vaccine for anthrax","volume":"110","author":"Leppla","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.05.057_b0035","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.057_b0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2019.05.057_b0045","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2019.05.057_b0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.05.057_b0055","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","article-title":"Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use","volume":"31","author":"Tozzi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.057_b0060","unstructured":"U.S. Department of Health and Human Services FaDA, Center for Biologics Evaluation and Research. Guidance for industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007."},{"key":"10.1016\/j.vaccine.2019.05.057_b0065","doi-asserted-by":"crossref","first-page":"151ra26","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.05.057_b0070","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/CVI.00469-14","article-title":"Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques","volume":"21","author":"Chen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.05.057_b0075","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1016\/j.vaccine.2015.05.091","article-title":"Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans","volume":"33","author":"Schiffer","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.057_b0080","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1016\/j.vaccine.2009.08.027","article-title":"Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132007","volume":"27","author":"Niu","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:00Z","timestamp":1759401180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19306942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":16,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19306942"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}